Hyperkalemia Treatment Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)

Hyperkalemia Treatment Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)

The hyperkalemia treatment market is poised to grow at a CAGR of 16.78% over the forecast period (2022 - 2027).

The Covid-19 pandemic is anticipated to have impacted the market during the pandemic phase. Since the beginning of the pandemic, there have been numerous discussions regarding the impact of Covid-19 on several areas of human health, and hyperkalemia is no exception. Several scientists conducted observational studies to find the correlation between hyperkalemia and Covid-19. For instance, in August 2021 an article was published titled “How SARS-CoV-2 Might Affect Potassium Balance via Impairing Epithelial Sodium Channels?” and as per the article there have been numerous reports of electrolyte issues, notably potassium imbalances, as frequent clinical symptoms of COVID-19. In this research, scientists have explored how SARS-CoV-2 may alter potassium homeostasis by reducing epithelial sodium channels' activity (ENaC) and explained the prevalence of hypokalemia. And concluded that there is a correlation between Covid-19 and hyperkalemia. Thus, the use of drugs to treat hyperkalemia increased during the pandemic. Therefore, the factors mentioned above are expected to have a considerable impact on the studied market.

Factors such as the increasing prevalence of hyperkalemia, rising focus on research and development, and an increasing number of strategic alliances among major market players are anticipated to drive the market growth. For instance, the article “Understanding Hyperkalemia (High Potassium)” published in March 2022 stated that high potassium levels or hyperkalemia (HK) affect 40 to 50% of people with chronic kidney disease (CKD), and nearly 40% of people with congestive heart failure (CHF) develop high potassium levels.

In addition, another article “Determinants of Hyperkalemia Progression Among Patients with Mild Hyperkalemia” published in October 2021 stated that when the research was conducted to characterize the progression of HK and identify the risk factors for HK progression, greater rates of HK progression were observed in individuals with advanced CKD stages, while the higher potassium levels were also found among heart failure, hypertension, and diabetes patients. Such prevalence of the disease is expected to demand the availability of drugs and diagnosis available to the target population and is predicted to contribute to the market growth.

Furthermore, the development activities by the market players in the form of product launches, acquisitions, mergers, and investments are also expected to enhance the market growth. Therefore, owing to the above-mentioned factors the market studied is expected to grow over the forecast period. However, the high cost of drugs is anticipated to hinder the market growth over the forecast period.

Key Market TrendsChronic Hyperkalemia Segment is Anticipated to Witness Growth Over the Forecast Period

Heart failure (HF) and chronic kidney disease (CKD) patients frequently have chronic hyperkalemia (cHK), a significant medical condition that can have detrimental effects and call for cautious management by cardiologists or nephrologists. Therefore, owing to the severity of the disease the cHK segment is anticipated to witness growth over the forecast period.

The data updated by the “National Kidney Foundation” in 2022 shows that when HK develops abruptly and potassium levels become extremely high, patients can experience chest pain, nausea, vomiting, shortness of breath, and heart palpitations. Also, severe/ chronic hyperkalemia can be a life-threatening condition and it necessitates urgent medical attention for the patient survival. Thus, such seriousness of the disease among the target population is expected to fuel the demand for drugs available for treatment which is anticipated to drive market growth.

Furthermore, the research article “Management of Chronic Hyperkalemia in Patients With Chronic Kidney Disease: An Old Problem With News Options” published in June 2021 mentioned that when a cohort study of 1,499 patients with cHK and CKD, heart failure, or diabetes mellitus was conducted with the follow up for 36 months, the annual healthcare cost per patient with cHK was calculated as double compared to mild hyperkalemia. Hence, the burden of the condition requires more targeted drugs or therapies for treatment, this is further expected to drive segment growth.

Therefore, owing to the factors mentioned above, the segment is anticipated to witness growth over the analysis period.

North America is Expected to Dominate the Market Over the Forecast Period

North America is anticipated to witness growth over the forecast period and dominate the market. Among other countries in the region, the United States is leading the market, due to factors such as an increase in healthcare expenditure, increasing research and developments, and rising prevalence of hypoleukaemia.​

As per the article “Hyperkalemia management in the emergency department: An expert panel consensus” published in October 2021, HK contributes to nearly 800,000 emergency department visits annually in the United States, and the prevalence of the disease is growing owing to the aging population and the growth in associated comorbidities. Such a high burden of the disease in the country is anticipated to demand the availability and development of advanced and effective drugs in the country. Thereby, driving the overall market growth in the region.

In addition, the data updated by the Centre for Disease Control and Prevention (CDC) in February 2022 shows that in the United States, nearly 37 million adults are estimated to have CKD, and 40% of people who live with severely reduced kidney function are not aware of having CKD. Additionally, as per the source mentioned above, approximately 360 people begin dialysis treatment for kidney failure in every 24 hours in the country. Thus, the burden of CKD is anticipated to increase the risk of hyperkalemia among the target population. This is expected to create urgent treatment options available for the condition. Which is further predicted to drive the market growth over the analysis period.

Therefore, owing to the factors mentioned above, the market studied is anticipated to witness growth in the region.

Competitive Landscape

The hyperkalemia treatment market is consolidated gloabbly and regionally, and is dominated by a few players. Few key market players in the market are AstraZeneca, Ardelyx, Vifor Pharma Management Ltd, Sanofi SA, and Perrigo Company PLC, among otehrs.

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support

Please note: This publisher does offer titles that are created upon receipt of order. If you are purchasing a PDF Email Delivery option above, the report will take approximately 2 business days to prepare and deliver.